NEW YORK (GenomeWeb) – KalGene Pharmaceuticals has inked an agreement with three Canadian research entities, the Sunnybrook Research Institute, the Centre for Imaging Technology Commercialization, and the Ontario Cancer Biomarker Network, to develop a companion diagnostic for metastatic cancer.

The Vancouver, British Columbia-based pharmaceutical firm will collaborate with its partners on a prognostic marker test along with a companion therapeutic specifically targeting aggressive cancers, such as metastatic breast, colon, and brain cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.